

# WELL WOMAN EXAMS IN PRIMARY CARE

Karen A. Fell, RNC, ANP, FNP-C

#### Objectives:

Develop a systematic approach to the well woman exam.

- Discuss the rationale for the 2012 changes to Pap smear schedule and follow up.
- Navigate available apps for Pap smear interpretation.
- Discuss Pap smear case studies focusing on follow up criteria.

#### Disclosures:

• I have no disclosures to discuss.





#### Purpose of Well Woman exam in Primary Care

- For many women, this may be their only visit for health care
  - Opportunity for education!
  - Encourage patient to become familiar with their body
- Health History
  - Reproductive health
  - Sexual health
  - STI/STD screening
- Elements:
  - Physical exam Head to Toe
  - Pelvic/gynecological exam

#### Health History

- Current medical issues
  - HTN, thyroid issues, hyperlipidemia, migraines, allergies, tobacco use, current medications, alcohol, drug use, etc.
- Mental/psychological issues
  - Depression, anxiety, bipolar, alcohol/drug abuse, etc.
  - Depression scale/measurement (EPDS, PHQ-9, etc.)
  - Intimate partner abuse/violence
- Reproductive health issues
  - Previous Pap history, mammograms, UTI history
- Sexual health issues

#### Depression Scales (Examples)

#### PATIENT HEALTH QUESTIONNAIRE-9 (PHQ-9)

Over the <u>last 2 weeks</u> , how often have you been bothere by any of the following problems? (Use "\sum " to indicate your answer)	d Not at all	Several days	More than half the days	Nearly every day
1. Little interest or pleasure in doing things	0	1	2	3
2. Feeling down, depressed, or hopeless	0	1	2	3
3. Trouble falling or staying asleep, or sleeping too much	0	1	2	3
4. Feeling tired or having little energy	0	1	2	3
5. Poor appetite or overeating	0	1	2	3
Feeling bad about yourself — or that you are a failure or have let yourself or your family down	0	1	2	3
7. Trouble concentrating on things, such as reading the newspaper or watching television	0	1	2	3
<ol><li>Moving or speaking so slowly that other people could have noticed? Or the opposite — being so fidgety or restless that you have been moving around a lot more than usual</li></ol>	e 0	1	2	3
Thoughts that you would be better off dead or of hurting yourself in some way	0	1	2	3
For office of	ODING0+		Total Score:	_
If you checked off <u>any</u> problems, how <u>difficult</u> have thes work, take care of things at home, or get along with othe		ade it for	you to do y	our/

Not difficult Somewhat at all difficult	Very difficult □	Extremely difficult
---	------------------------	---------------------

Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.

#### Edinburgh Postnatal Depression Scale<sup>1</sup> (EPDS) Address: \_ Your Date of Birth: Baby's Date of Birth: As you are pregnant or have recently had a baby, we would like to know how you are feeling. Please check the answer that comes closest to how you have felt IN THE PAST 7 DAYS, not just how you feel today. Here is an example, already completed. I have felt happy: Yes, most of the time This would mean: "I have felt happy most of the time" during the past week. No. not very often Please complete the other questions in the same way. □ No, not at all In the past 7 days: 1. I have been able to laugh and see the funny side of things \*6. Things have been getting on top of me As much as I always could Yes, most of the time I haven't been able Not quite so much now to cope at all Yes, sometimes I haven't been coping as well Definitely not so much now as usual No, most of the time I have coped quite well 2. I have looked forward with enjoyment to things No, I have been coping as well as ever As much as I ever did Rather less than I used to \*7 I have been so unhappy that I have had difficulty sleeping Definitely less than I used to Yes, most of the time Hardly at all Yes, sometimes Not very often \*3. I have blamed myself unnecessarily when things No. not at all went wrong Yes, most of the time \*8 I have felt sad or miserable Yes, some of the time Yes, most of the time Yes, quite often Not very often No, never Not very often No, not at all 4. I have been anxious or worried for no good reason \*9 I have been so unhappy that I have been crying No. not at all Hardly ever Yes, most of the time Yes, very often Only occasionally No. never \*5 I have felt scared or panicky for no very good reason \*10 The thought of harming myself has occurred to me Yes, sometimes Yes, quite often No not much Sometimes No, not at all Hardly ever <sup>1</sup>Source: Cox, J.L., Holden, J.M., and Sagovsky, R. 1987. Detection of postnatal depression: Development of the 10-item Edinburgh Postnatal Depression Scale. British Journal of Psychiatry 150:782-786 <sup>2</sup>Source: K. L. Wisner, B. L. Parry, C. M. Piontek, Postpartum Depression N Engl J Med vol. 347, No 3, July 18, 2002, Users may reproduce the scale without further permission providing they respect copyright by quoting the names of the

authors, the title and the source of the paper in all reproduced copies.

#### Reproductive Health

- Pregnancy history
  - Gravida, para, (term, preterm, spontaneous/elective abortions, living children); G4P2113
  - Desire more children?
- Contraception use
  - Previous, current, desired
- Chromosome disorders (family history)
  - Down Syndrome, Cleft palate/lip, Trisomy disorders, etc.
- Infertility treatments/workup
  - Clomid, IUI, IVF
- Gynecological issues/previous surgeries
  - Vaginal, cervical, uterine, ovarian, tubal surgeries; abnormal uterine bleeding, etc.

### Contraceptive Guide

 https://www.cdc.gov/reproductivehealth/contraception/pdf/summa ry-chart-us-medical-eligibility-criteria\_508tagged.pdf

#### **Summary Chart of U.S. Medical Eligibility Criteria for Contraceptive Use**

<b>R</b> 1000	Centers for Disease Control and Prevention National Center for Chron Disease Prevention and Health Promotion
---------------	--

Condition	Sub-Condition	Cu-IUD		LNG-IUD	Impla	nt	D	MPA		POP	C	HC
		I C		I C	1	С	- 1	С	П	С	1	0
Age		Menarch	ne l	Menarche	Menare	he	Me	narche	Me	narche	Men	arch
		to	~	to	to		""	to	*****	to		to
		<20 yrs:	2	<20 yrs:2	<18 yr	s: <b>1</b>	<18	B yrs:2	<1	B yrs:1	<40	yrs:
		≥20 yrs:	1	≥20 yrs:1	18-45 yrs:1		18-4	15 yrs:1	18-4	15 yrs:1	≥40	VTS:
			7		>45 yr			5 yrs:2		5 yrs:1		,
Anatomical	a) Distorted uterine cavity	4		4								
abnormalities	b) Other abnormalities	2	$\neg$	2								
Anemias	a) Thalassemia	2	_	1	1			1		1		1
	b) Sickle cell disease‡	2	7	1	1			1		1		2
	c) Iron-deficiency anemia	2	_	1	1			1		1		1
Benign ovarian tumors	(including cysts)	1	-	1	1			1		1		1
Breast disease	a) Undiagnosed mass	1	_	2	2"			2*		2*		2*
	b) Benign breast disease	1		1	1			1		1		1
	c) Family history of cancer	1	_	1	1			1		1		<u>i</u>
	d) Breast cancer <sup>‡</sup>		$\top$						т			
	i) Current	1		Δ	4			4		4		4
	ii) Past and no evidence of current											_
	disease for 5 years	1		3	3			3		3		3
Breastfeeding	a) <21 days postpartum		4		2*			2*		2*		<b>4</b> *
	b) 21 to <30 days postpartum		4									
	i) With other risk factors for VTE		4		2*			2*	_	2*		3*
	ii) Without other risk factors for VTE		4		2*			2*		2*		3*
	c) 30-42 days postpartum		$\perp$									
	i) With other risk factors for VTE		4		1*			1*		1*		3*
	ii) Without other risk factors for VTE		$\perp$		1*			1*		1*		2*
	d) >42 days postpartum		4		1*			1*		1*		2*
Cervical cancer	Awaiting treatment	4 2		4 2	2			2		1		2
Cervical ectropion		1		1	1			1		1		1
Cervical intraepithelial neoplasia		1		2	2			2		1		2
Cirrhosis	a) Mild (compensated)	1		1	- 1			1		1		1
	b) Severe <sup>‡</sup> (decompensated)	1		3	3			3		3		4
Cystic fibrosis‡		1*		1*	1*			2*		1*		1*
Deep venous thrombosis (DVT)/Pulmonary	a) History of DVT/PE, not receiving anticoagulant therapy		Т									
embolism (PE)	i) Higher risk for recurrent DVT/PE	1		2	2			2		2		4
	ii) Lower risk for recurrent DVT/PE	1		2	2			2		2		3
	b) Acute DVT/PE	2	$\neg$	2	2			2		2		4
	c) DVT/PE and established anticoagulant		$\neg$									
	therapy for at least 3 months											
	i) Higher risk for recurrent DVT/PE	2		2	2			2		2		4*
	ii) Lower risk for recurrent DVT/PE	2		2	2			2		2		3*
	d) Family history (first-degree relatives)	1	T	1	1			1		1		2
	e) Major surgery		Т									
	i) With prolonged immobilization	1		2	2			2		2		4
	ii) Without prolonged immobilization	1		1	1			1		1		2
	f) Minor surgery without immobilization	1		1	1			1		1		1
Depressive disorders	- /	1*		1*	1*			1*		1*		1*

Condition	Sub-Condition	Cu-	IUD	LNG	-IUD	Implant	DMPA	POP	CHC
			С	_	С	I C	I C	I C	I C
Diabetes	a) History of gestational disease	1				1	1	1	1
	b) Nonvascular disease			-					
	i) Non-insulin dependent	1	1	- :	2	2	2	2	2
	ii) Insulin dependent	1	1		2	2	2	2	2
	c) Nephropathy/retinopathy/neuropathy <sup>‡</sup>	1	i			2	3	2	3/4*
	d) Other vascular disease or diabetes							_	
	of > 20 years' duration <sup>‡</sup>	1		2	2	2	3	2	3/4*
Dysmenorrhea	Severe	2	2	1		1	1	1	1
Endometrial cancer <sup>‡</sup>		4	2	4	2	1	1	1	1
Endometrial hyperplasia		1		1		1	1	1	1
Endometriosis		- 2	2	1		1	1	1	1
Epilepsy <sup>‡</sup>	(see also Drug Interactions)	1	1			1*	1*	1*	1*
Gallbladder disease	a) Symptomatic								
	i) Treated by cholecystectomy	1	1	- 2	2	2	2	2	2
	ii) Medically treated	1	1			2	2	2	3
	iii) Current	1	1		2	2	2	2	3
	b) Asymptomatic					2	2	2	2
Gestational trophoblastic				_	_				
disease <sup>‡</sup>	postevacuation)								
	i) Uterine size first trimester	1*		1*		1*	1*	1*	1*
	ii) Uterine size second trimester	- 2	2*	2*		1*	1*	1*	1*
	b) Confirmed GTD								
	i) Undetectable/non-pregnant	1*	1*	1*	1*	1*	1*	1*	1*
	ß-hCG levels	1*	1*	1*	1*	1*	1×	1*	1*
	ii) Decreasing B-hCG levels	2*	1*	2*	1*	1*	1*	1*	1*
	iii) Persistently elevated B-hCG levels								
	or malignant disease, with no	2*	1*	2*	1*	1*	1*	1*	1*
	evidence or suspicion of intrauterine disease	_		_					
	iv) Persistently elevated B-hCG levels								
	or malignant disease, with evidence	4*	2*	4*	2*	1*	1*	1*	1*
	or suspicion of intrauterine disease		_	7	_				
Headaches	a) Nonmigraine (mild or severe)	1	1			1	1	1	1*
	b) Migraine								
	i) Without aura (includes menstrual	1				1	1	1	2*
	migraine)					_		- 1	2-
	ii) With aura	- 1	1	1		1	1	1	4*
History of bariatric	a) Restrictive procedures	- 1	_			1	1	1	1
surgery <sup>‡</sup>	b) Malabsorptive procedures	1				1	1	3	COCs: 3
	b) Maiabsorptive procedures	1	•				- 1	3	P/R: 1
History of cholestasis	a) Pregnancy related	1	1	1		1	1	1	2
	b) Past COC related	1	1	- 2	2	2	2	2	3
History of high blood									
pressure during		1	1	1	1	1	1	1	2
pregnancy									
History of Pelvic surgery		1	_			1	1	1	1
HIV	a) High risk for HIV	2	2	2	2	1	1*	1	1
	b) HIV infection					1*	1*	1*	1*
	i) Clinically well receiving ARV therapy	1	1	1	1	If on tr	eatment, se	e Drug Inter	actions
	ii) Not clinically well or not receiving ARV	2	1	2	1	If on tr	eatment se	e Drug Inter	actions
	therapy*			_		5.1 (	, se	rug miten	

Key:

1 No restriction (method can be used)
2 Advantages generally outweigh theoretical or proven risks
4 Unacceptable health risk (method not to be used)

Abbreviations: C-continuation of contraceptive method; CHC-combined hormonal contraception [pill, patch, and, ring]; CDC-combined onal contraceptive; Cu-IUD-copper-containingcitizatative device; DMR+ depot medioappropertiesne actate; i-initiation of contraceptive method; ING-IUD-leoporagestarl-infeasing intrauturine device; NA+rost applicable; POP-progestion-only pill; PIP-spatch/ving st Condition that exposes a woman to increased risk as a result of programory. "Please see the complete guidance for a clarification to this classification wow.act.gov/exposition-tealth/universidedpregnancy/USMC/EIM.

#### Summary Chart of U.S. Medical Eligibility Criteria for Contraceptive Use




Condition	Sub-Condition	Cu-	IUD	LNG	-IUD	Impl	ant	D	MPA		POP	(	CHC
		- 1	С	- 1	С	1	С	Т	С	- 1	С	- 1	C
Hypertension	a) Adequately controlled hypertension		1*		1*	11	*		2*		1*		3*
,	b) Elevated blood pressure levels												
	(properly taken measurements)												
	i) Systolic 140-159 or diastolic 90-99		1*		1* 1*				2*	1*		3*	
	ii) Systolic ≥160 or diastolic ≥100‡		1*		2*	2			3*		2*	4*	
	c) Vascular disease		1*		2*	2	*		3*		2*		4*
Inflammatory bowel disease	(Ulcerative colitis, Crohn's disease)		1		1	- 1			2		2	2	2/3*
Ischemic heart disease‡	Current and history of		1	2	3	2	3		3	2	3		4
Known thrombogenic mutations <sup>‡</sup>	,		1*		2*	2	H		2*		2*		4*
Liver tumors	a) Benign												
	i) Focal nodular hyperplasia		1		2	2			2		2		2
	ii) Hepatocellular adenoma‡		1		3	3			3		3		4
	b) Malignant <sup>†</sup> (hepatoma)		1		3	3			3		3		4
Malaria			1		1	1			1		1		1
Multiple risk factors for atherosclerotic cardiovascular disease	(e.g., older age, smoking, diabetes, hypertension, low HDL, high LDL, or high triglyceride levels)		1		2	2	*		3*		2*	3	3/4*
Multiple sclerosis	a) With prolonged immobility		1		1	1			2		1		3
	b) Without prolonged immobility		1		1	- 1			2		1		1
Obesity	a) Body mass index (BMI) ≥30 kg/m <sup>2</sup>	1		1		1			1		1		2
,	<li>b) Menarche to &lt;18 years and BMI ≥ 30 kg/m²</li>		1		1	1			2		1		2
Ovarian cancer <sup>‡</sup>			1		1	1			1		1		1
Parity	a) Nulliparous		2		2	- 1			1		1		1
	b) Parous		1		1	1			1		1		1
Past ectopic pregnancy			1		1	- 1			1		2		1
Pelvic inflammatory	a) Past												
disease	i) With subsequent pregnancy	1	1	1	1	1			1		1		1
	ii) Without subsequent pregnancy	2	2	2	2	- 1			1		1		1
	b) Current	4	2*	4	2*	- 1			1		1		1
Peripartum cardiomyopathy <sup>‡</sup>	a) Normal or mildly impaired cardiac function												
	i) <6 months		2		2	1			1		1		4
	ii) ≥6 months		2		2	1			1		1		3
	<ul> <li>b) Moderately or severely impaired cardiac function</li> </ul>		2		2	2			2		2		4
Postabortion	a) First trimester		1*		1*	- 11			1*		1*		1*
	b) Second trimester		2*	2* 1*		1*		1* 1*		1*		1*	
	c) Immediate postseptic abortion		4		4	11	*		1*		1*		1*
Postpartum	a) <21 days					1			1		1		4
(nonbreastfeeding	b) 21 days to 42 days												
women)	i) With other risk factors for VTE					1			1		1		3*
	ii) Without other risk factors for VTE					1			1		1		2
	c) >42 days					1			1		1		1
Postpartum	a) <10 minutes after delivery of the placenta												
(in breastfeeding or non-	i) Breastfeeding		1*		2*								
breastfeeding women,	ii) Nonbreastfeeding		1*		1*								
including cesarean delivery)	b) 10 minutes after delivery of the placenta to <4 weeks		2*		2*								
	c) ≥4 weeks		1*		1*								
	d) Postpartum sepsis		4		4								

Condition	Sub-Condition	Cu-	IUD	LNG	-IUD	Implant	DM	PA	POP	CHC
		1	С	1	С	I C	1	С	I C	I C
Pregnancy		4	*	4	*	NA*	N	A*	NA*	NA*
Rheumatoid	a) On immunosuppressive therapy	2	1	2	1	1	2/	3*	1	2
arthritis	b) Not on immunosuppressive therapy	_		_	-	1	2	,	1	2
Schistosomiasis	a) Uncomplicated			_	<del>-</del>	1	1		1	1
Jen 13 to 3 of 11 to 3 of 1	b) Fibrosis of the liver <sup>‡</sup>	-			<del>i                                    </del>	1	1		1	1
Sexually transmitted	a) Current purulent cervicitis or chlamydial									
diseases (STDs)	infection or gonococcal infection b) Vaginitis (including trichomonas vaginalis	4	2*	4	2*	1	1		1	1
	and bacterial vaginosis)	2	2	2	2	1	1		1	1
	c) Other factors relating to STDs	2*	2	2*	2	1	1		1	1
Smoking	a) Age <35	1			1	1	1		1	2
	b) Age ≥35, <15 cigarettes/day	1	_	_	1	1	1		1	3
	c) Age ≥35, ≥15 cigarettes/day	1	_		1	1	1		1	4
Solid organ	a) Complicated	3	2	3	2	2	2		2	4
transplantation <sup>‡</sup>	b) Uncomplicated		2		2	2	2		2	2*
Stroke <sup>‡</sup>	History of cerebrovascular accident	1			2	2 3	3		2 3	4
Superficial venous	a) Varicose veins	1			1	1	1		1	1
disorders	b) Superficial venous thrombosis	-			1	1	1		1	3*
	(acute or history)		_		<u> </u>					3"
Systemic lupus erythematosus <sup>‡</sup>	<ul> <li>a) Positive (or unknown) antiphospholipid antibodies</li> </ul>	1*	1*		3*	3*	3*	3*	3*	4*
	b) Severe thrombocytopenia	3*	2*	2*		2*	* 3*		2*	2*
	c) Immunosuppressive therapy	2*	1*	2*		2*	2* 2*		2*	2*
	d) None of the above	1*	1*		2*	2*	2*	2*	2*	2*
Thyroid disorders	Simple goiter/ hyperthyroid/hypothyroid	1			1	1	1		1	1
Tuberculosis <sup>‡</sup>	a) Nonpelvic	1	1	1	1	1*	1	*	1*	1*
(see also Drug Interactions)	b) Pelvic	4	3	4	3	1*	1	*	1*	1*
Unexplained vaginal bleeding	(suspicious for serious condition) before evaluation	4*	2*	4*	2*	3*	3	*	2*	2*
Uterine fibroids	CYGGGGGG		2		2	1	1		1	1
Valvular heart	a) Uncomplicated	-				1	1		i	2
disease	b) Complicated <sup>‡</sup>		_	_	<del>-</del>	1	1		i	4
Vaginal bleeding patterns	a) Irregular pattern without heavy bleeding			1	1	2	2		2	1
reginar breezing parters	b) Heavy or prolonged bleeding		2*	1*	2*	2*		¥	2*	1*
Viral hepatitis	a) Acute or flare			-	-	1	1		1	3/4* 2
vital Hepatitis	b) Carrier/Chronic	-		_	<del></del>	1	1	_	1	1 1
Drug Interactions	b) carrier/enrone				_		_			
Antiretroviral therapy	Fosamprenavir (FPV)									
All other ARV's are 1 or 2 for all methods.	rosamprenavii (FFV)	1/2*	1*	1/2*	1*	2*	2	¥	2*	3*
Anticonvulsant therapy	a) Certain anticonvulsants (phenytoin, carbamazepine, barbiturates, primidone, topiramate, oxcarbazepine)	1			1	2*	1	*	3*	3*
	b) Lamotrigine	-		-	1	1	1		1	3*
Antimicrobial	a) Broad spectrum antibiotics	-			1	1	1		1	1
therapy	b) Antifungals		_	_		1	1		1	1
	c) Antiparasitics		_	1		1			1	1
	7			_	<del> </del>		1*			_
ccni-	d) Rifampin or rifabutin therapy	1		_		2*	_		3*	3*
SSRIs			_			1	1		1	
St. John's wort		- 1				2	1		2	2

Updated July 2016. This xummary sheet only contains a subset of the recommendations from the U.S.MIC. For complete guidance, see http://www.cdc.gov/reproductivehealth/ unintendopregrams/USMEC.htm. Most contraceptive methods do not protect against sexually transmitted diseases (STDs). Consistent and correct use of the male lates condom reduces the risk of SD.D and HW.

CS266008-A

#### Contraceptive Conversation Starter



# Sexual Health (based on age)

- Sexual orientation
  - Heterosexual, homosexual, bisexual
- Sexual experiences
  - Dyspareunia, ability/inability to reach orgasm, etc.
- Sexual practices
  - Oral, anal, vaginal, self-stimulation (toys, masturbation)
- History of sexual abuse/rape
  - Type, current issues, impact on sexual health/exams

### STI/STD Screening

- Behaviors that increase STI/STD risk
  - Multiple sex partners; new sex partners, etc.
- History of STI/STD
  - Review past hx of STD diagnosis; treatments; recurrence of infection
- Protection against STI/STD
  - Does the patient use barrier devices?
  - Does the patient engage in high risk behaviors?
  - Knowledge of what is out there areas with higher rates of certain STDs.

#### Sexually Transmitted Diseases

- According to the CDC: STDs in the US for 2015
  - Chlamydia: 1,526,658 reported cases, increase of 6% since 2014
  - Gonnorrhea: 395,216 reported cases, increase of 13% since 2014
  - Syphillis (primary and secondary): 23,872 reported cases, 19% increase since 2014
  - Syphillis (congenital): 487 reported cases, 6% increase since 2014
- Most GC/CT cases occur among 15-24 year olds
- Alaska (2015):
  - Ranked 1st among the 50 states for chlamydia
  - Ranked 8<sup>th</sup> for gonorrhea
  - Women were 2.2 times higher than men for chlamydial infections
  - Ranked 49<sup>th</sup> for syphillis

#### STD Screening Guidelines

- https://www.cdc.gov/std/tg2015/screening-recs-2015tgrevised2016.pdf
- Chlamydia:
  - Sexually active women under age 25; 25 and older at-risk; retest 3 months after treatment
  - All pregnant women under age 25; 25 and older at-risk women; retest in 3<sup>rd</sup> trimester for women under 25 or at risk; perform TOC 3-4 weeks after tx
- Gonorrhea:
  - Sexually active women under age 25; 25 and older at-risk; all pregnant women 25 and older at-risk; retest 3 months after treatment
- Syphilis:
  - All pregnant women at first prenatal visit and retest in early 3<sup>rd</sup> trimester and at delivery if at high risk

### CDC Summary of STD Treatment Guidelines

https://www.cdc.gov/std/tg2o15/default.htm

Secretary Lagislands  Annual A	These community gradefuses pellicut the 2003 CDX for the evaluation, and incommon of any partners of DISEASE	RECOMMENDED Rx	rent Arpert	es; Summary of 2015 CDC Treatm.  the ser annoted to a source of closed publish. An impossion of some Complete publishers can be submit value at warm the pu- DOSE/ROUTE	empower of STD to resource in parties assessment. Providen can are real transcent in for rating 1 (500 CDC 2000 () 800 2)(2-4030). ALTERNATIVES	
Projection   Pro			08.	100 ag early Scient by 1 ages	Special Control ( ) and ( ) are	
Carbodies and Services 1992. It is a state of the company of the c		per-materia più 1750 dinfamora tress 25°	OR.	One I g applicates settlerapisally in the far I days. One I g applicates settlerapisally of herbina fac I days.	Similarde 1 g welly lockly the 1-days charteness NH agrandy Inches for 7-days charteness order 100 agrant/agrads of bulliage for 3-days	2
Tables you file of the common	Cervicitis		08.	I g coulty in a ringle door.   Consider conceaser bestimen for pure 100 ang coulty (in day for 7 days)   presented to a floor based of the conceaser bestimen for the conceaser of the conceaser	construction of the high of properties or three to a community other the providence of the will be of the construction of the providence of the will be of the construction of the provided for write and the construction of the provided for writer and the construction of the	-
waterward waterward of the company o	hlanydial Infections	infrares income	18.	To easily in a cough down	entally of billion on count or exceed or of 700.6° writing it and provides anythrough in hose? Till any enalty the later the 7 days and the country of the later of the later than the 7 days.	***
The company of the co	Hipman) <sup>2</sup>	selectors'		T g melli se e imgle žime	investment (Ning) bette statt for 1 days districted 100 and stattly for 1 days districted 100 and settly for the first 1 days with the settle stattly for the first 1 days with the settle settle stattly for the first 1 days withdrawment favor 110 and width the first first 1 days withdrawment favor 110 and width the first first 1 days	Acres a
The company of the co	that and Outliers I 40 kg/ originals, need	and the second second	OK.	15 mg/kg/key sorder (4 Montal Armes Andry Ser 19 June	er flessgran relicious page 400 og ordly 6x der for 14 days  * Zon are tracked on the reflectiveness and uploant Anni of antinenessia.	
Annual control of the			48.	10 mg/kg/dec south; (4 deceled dozen) dealty the (4 dece.	* automore 25 mg/kg/kg malit, 1 does may be 3 Acro	
About the control of						
About a series of the control of the	For scale epolishments more blody (powell's) wroughy transported CT and GC	refrance description	MUN.	700 mg/86° is a single dow 100 mg anally 2s tiler tile 10 days		
Secretary Simples  Secretary Sim	For scient equilibrium soort labely cannot by executive transmitted characters and procedure	Indicace	PL05	250 mg/hf in a single door		
inclined Experts SimpleX and growing the same part departs and provided inclined and provided provided in the control of the c	and marrie organism (may who provide positive and set).	efereix	OR .	300 ang sendir 1s day the 10 days 100 ang sendir 1s day the 10 days		
with the larger in a mean peak larger in a m		iredocate strenge	OR	100 sag wally to the 64 Maco 100 sag wally to the 64 Maco		
The control of the control products and prod	Genital Herpes Simplex	andre	100			
Section of the contemporal beautiful and section of the contemporal beautiful	and chancel represeds of greated bengen	Appliers	COR.	200 mg unity to the fire 1-10 mys <sup>-1</sup> Le sealth for the day 1-10 days <sup>-1</sup>		
Section of the control of the contro		Services*		200 may workly 2n day the 3 50 shore?		
Section of the control of the contro	production for security peaks being	andre .	OR	NO sag made in the fact of them.		
Section of the control of the contro		tale referen	OR	300 mag versity its than the T days		
Section of the control of the contro		See of Section 1	08.	1.g wealth 1 to that The 7-filters 1.27 kag wealth 2 is they five 1 days		
Section of the control of the contro		Sanctory'		1000 mg unity (solin) for 1 days" 1000 mg unity men, followed by 250 mg /n day for 2 days		
And the second s	agence forgy to recent postdieps	acyclicia talacyclinas <sup>2</sup>	OR.	MIO ang mulio 20,000 TOS mag mulio 2n,000		
An advanced for the control of the c		roley-bright Selectories	tit.	I g really uses a fire 200 mag made In-ther		
And the property of the proper	to consended regimen for equiple solution in	andres	OR.	400 mg anally harter the 3-10 show		
Formation (1997)  The control behaviors of the second of t				100 agoustly 2s day for 5 th days		
Formation (1997)  The control behaviors of the second of t	eronomist reports to buly represent lenge is provin with NEV astronia	neithera rains policina	CE	600 800 aug coally 3 for last 500 aug coally 3s disc		
Agin and anomae of gain words of the control of gain words of the control of gain words of gain word	Conduct History	Section Section				
Agin and anomae of gain words of the control of gain words of the control of gain words of gain word		■ compared 5.75% or 5% comm.  position 6.7% solution or pil	08.	Ser couples CDC guildian.		
Contact of the contac	mend profit and promit wark	marchinina (1% minute)				
seminorary of the control of the con		Crosterapy	OR.	While some second with delite country is so somely	<ul> <li>probabilities error 10°s 27°s in compound teacher of broaden due to considered the provider editionaries treatment of other adherman to the</li> </ul>	
And Authors and a second of Experiment of Authors and		to himselfic and or behinnestic and RPs 90% begind reason.	OR.		decommendations for application.	
And Additional of all contents					planted/scatter ferrigin repeat catedorie	-
Production Parks  Security Control Parks  Final 2 (a give to a ring) that  security Control Parks  Final 2 (a give to a ring) that  security Control Parks  Final 2 (a give to a ring) that  security Control Parks  Final 2 (a give to a ring) that  security Control Parks  Final 2 (a give to a ring) that  security Control Parks  Final 2 (a give to a ring) that  security Control Parks  Final 2 (a give to a ring) that  security Control Parks  Final 2 (a give to a ring) that  security Control Parks  Final 2 (a give to a ring) that  security Control Parks  Final 2 (a give to a ring) that  security Control Parks  Final 2 (a give to a ring) that  security Control Parks  Final 2 (a give to a ring) that  security Control Parks  Final 2 (a give to a ring) that  security Control Parks  Final 2 (a give to a ring) that  security Control Parks  Final 2 (a give to a ring) that  security Control Parks  Final 2 (a give to a ring) that  security Control Parks  Final 2 (a give to a ring)	Gonococcal Infections <sup>21</sup>	telescone .	BUN	Till og til en ogs tre	* Durbania y art maletin	
Production Parks  Security Control Parks  Final 2 (a give to a ring) that  security Control Parks  Final 2 (a give to a ring) that  security Control Parks  Final 2 (a give to a ring) that  security Control Parks  Final 2 (a give to a ring) that  security Control Parks  Final 2 (a give to a ring) that  security Control Parks  Final 2 (a give to a ring) that  security Control Parks  Final 2 (a give to a ring) that  security Control Parks  Final 2 (a give to a ring) that  security Control Parks  Final 2 (a give to a ring) that  security Control Parks  Final 2 (a give to a ring) that  security Control Parks  Final 2 (a give to a ring) that  security Control Parks  Final 2 (a give to a ring) that  security Control Parks  Final 2 (a give to a ring) that  security Control Parks  Final 2 (a give to a ring) that  security Control Parks  Final 2 (a give to a ring) that  security Control Parks  Final 2 (a give to a ring) that  security Control Parks  Final 2 (a give to a ring)	oblides of the seconditional presents of				collectors 400 mg study in a single drive antiferenties. I a mode in a single drive	9
And the second of the second o	advision of the cercus, levelus, and resions				* Explorages deg:	
And the second of the second o					genedicencie. Oit ing nodity in a segler done authorizeda 2 g wally in a single done.	3
And the second process of the second process					previous (40 mg M angle dox	-)
The companion of the co	Securit'	refrience	RICK	(Mag N in single free	Proceedings of the second	
Together and processes and processes of the processes of	Ampailment Commission of the C	be couple (DC pickbar)		1 Compared to the control of the con		
State of the segment and promote many proposal and promote and pro	Mally and addressess		PLINE	T g fill in a usujin door		
Sequence of the property of th	hites (191 kg) respected, mind pharmaged	refrance"				
Nonpersonal Particular (Note)  Promote and manusch (Note)  Remaind and Manusch (Note)	jmphogrannioma renerenm	desperies.		100 mg entity looker the 21 days		
The control of the co		pollowers."	100	Ly make in a small than	embraces have 100 ag early to be \$4.7 kgs	2
The control of the co				and and the second	investments lift sig to the first of days.  often sig billing to the bill days.	3
wedwards with the part of the	Process and recognition (ACC)	Most autually decided with discoprofuse: and present as		Lighted to a completion		
Policicalizato Publica  Policicalizato  Policicalizato		Man who field a registery of authoristy in:				
Well promise of the control of the c		Total Control of the		Bill old might be get a 1 with		
Professional Parties  Annual P		Sightly porceions.				
Standard Sta	Budden for the Budden	Section 10			and the State and State an	
Standard Sta		promises with pigernery horsests	-	Apply to affected area, weak off after 15 magnets	remarks [16 µg/kg maly entered in 2 weeks	
Security of the control of the contr	Terric Inflammatory	Colonia Colonia	nin	2 g PC wanty 12 house	Angenitia Saltanias ) g IV even d bean	9
Scales and the second formation of the degree of the second formation of the s	nicene.	Control (Control (Con			Description 100 agreetly in IV every 12 hours	
Section 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1		Desportes	Stop	130 erg coulty or FF errory 17 boson		
Columnic State of the		Recommended Intermediate Oral Regimes				
Columnic State of the		Describe	William	100 mg mile train a day by 16 days		
Scales  Section  Sect		200	DR	man and many moves a stay for the stays		
Science   Section   Sectio		Personal	FLIX	1 g mills administrati concentrate in a ringle from	The complete has of monopological regions can be found in	
Science   Section   Sectio		Mondak	- WILLIAM A	THE ME WHITE E BUY BY THE BUYS		
Windstramments 1   1   1   1   1   1   1   1   1   1			in.	Apply to all areas of body firms sock down, wook off after \$ 19 hours.	Studies PV* I ex. of latine or H g of return, applied their to all areas of the body from the next street, wish off after 8 tooss.	
ten i i me, ten indivisione feminis i me service promotifici di la prime della di la comitanti di la com	yphitis	Securities provide 0		J.A. nullivia man D.C. at. a single-drive	despression ** 100 mg Ju day for 14 days when to like ** 100 mg westy during the 14 days	
Separate Sep		Securities provides V		I hadron man bling I many such at I were provide	description of this payment is the state of	×
Trickensonialistic Ministry and Commission of the Commission of th				(77 million mate total)	NAME OF THE PARTY AND POST OF THE PARTY.	ľ
Cognisi right:  Description:  Description:	transphile.	agents in the periods 0		15-34 author-services day, electrowed in 5-4 author-service?	pre-see provides G. J. R.MC SK In Sect.	,
Allow Freeze consistent engine to the consistent of the consistent	· ·	Decision COC markets		every 4 bears of continuous authoria, for 19-19 days	perfected BH ag scale factor, both to 10 to him.	
Sales Come 1 year, from of places (approx. from of places))  Frichersonnian's control of the places (approx. from of places)  Frichersonnian's control of the places (approx. from of places)  Frichersonnian's control of the places (approx. from of places)  Frichersonnian's control of the places (approx. from of places)  Frichersonnian's control of the places (approx. from of places)  Frichersonnian's control of the places (approx. from of places)  Frichersonnian's control of the places (approx. from of places)  Frichersonnian's control of the places (approx. from of places)  Frichersonnian's control of the places (approx. from of places)  Frichersonnian's control of the places (approx. from of places)  Frichersonnian's control of the places (approx. from of places)  Frichersonnian's control of the places (approx. from of places)  Frichersonnian's control of the places (approx. from of places)  Frichersonnian's control of the places (approx. from of places)  Frichersonnian's control of the places (approx. from of places)  Frichersonnian's control of the places (approx. from of places)  Frichersonnian's control of the places (approx. from of places)  Frichersonnian's control of the places (approx. from of places)  Frichersonnian's control of the places (approx. from of places)  Frichersonnian's control of the places (approx. from of places)  Frichersonnian's control of the places (approx. from of places)  Frichersonnian's control of the places (approx. from of places)  Frichersonnian's control of the places (approx. from of places)  Frichersonnian's control of the places (approx. from of places)  Frichersonnian's control of the places (approx. from of places)  Frichersonnian's control of the places (approx. from of places)  Frichersonnian's control of the places (approx. from of places)  Frichersonnian's control of the places (approx. from of places)  Frichersonnian's cont		Securitive probable G		10,000 mainting Diff in a simple from (measures 2.6 million matri)	bases any belongs spale.	
Frichessonianis  OR 2 with a registron  outstands  (2 with a registron  particularly  (3 with a registron  particularly  (4 with a registron  outstands)  (5 with a registron  outstands)	billion Lond of you, latest of advances duration	become provide C		10.000 min/kg Dd for 1 down at 1 week asterolo		
permanents 1996 and Table 1976 and	Trichomoniasis	personal contract	08	I g wally is a single door	memorahanin'i 100 mg Sariny for 7 days	1
Fittis regions first controlled OR 2 centre for Total						
mark constants OR 2g could fee 7 days		and the state of t				
	tracked of mineral forbassions	ortrousers by		199kg edit 2xiky fe 7 Aus		

### Expedited Partner Therapy (EPT)

- Treating the sex partner(s) of a patient diagnosed with gonorrhea or chlamydia without first seeing/examining said partner(s)
  - Permissible in 41 states to include Alaska
    - "unprofessional conduct" includes the following... prescribing, dispensing, or furnishing a prescription medication to a person without first conducting a physical examination of that person...; this paragraph does not apply to prescriptions written or medications issued... for expedited partner therapy for sexually transmitted diseases. Alaska Admin. Code tit. 12 40,967(29)(B)
  - Potentially allowable in 7 states
  - Prohibited in 2 states (Kentucky and South Carolina)
- New treatment guidelines for gonorrhea (2012):
  - IM ceftriaxone (250mg) plus azithromycin (1g) slurry
  - EPT is not possible for IM injections in most cases
- As a clinician, you make the decision to utilize EPT
  - Education about treatment guidelines, medication allergies, medication warnings

#### Physical Exam

- Head-to-toe fashion:
  - Head
    - Dentition, hair growth/appearance (dry, brittle, etc.), peircings
  - Thyroid exam
    - Anterior and/or posterior approach
  - Body habitus
    - Note hair distribution, fat distribution (obesity, etc.), scars, tattoos, skin assessment, etc.
  - Breast exam
    - Inspect/palpate breasts and lymph nodes, piercings
  - Abdominal exam
    - Palpation, auscultation, piercings
  - Pelvic exam
    - Pap smear, bimanual exam, piercings

## Cervical Cancer Screening Guidelines

#### https://www.cdc.gov/cancer/cervical/pdf/guidelines.pdf


#### Cervical Cancer Screening Guidelines for Average-Risk Women<sup>a</sup>

		American Cancer Society (ACS), American Society for Colposcopy and Cervical Pathology (ASCCP), and American Society for Clinical Pathology (ASCP) <sup>1</sup> 2012	U.S. Preventive Services Task Force (USPSTF) <sup>2</sup> 2012	American College of Obstetricians and Gynecologists (ACOG) <sup>3</sup>	Society of Gynecologic Uncology (SGU) and the American Society for Colposcopy and Cervical Pathology (ASCCP): Interim clinical guidance for nrimary hrHPV testing <sup>6</sup> 2015
When to start screen	ning <sup>b</sup>	Age 21. Women aged <21 years should not be screened regardless of the age of sexual initiation or other risk factors.	Age 21. (A recommendation) Recommend against screening women aged <21 years (D recommendation).	Age 21 regardless of the age of onset of sexual activity. Women aged <21 years should not be screened regardless of age at sexual initiation and other behavior-related risk factors (Level A evidence).	Refer to major guidelines.
Statement about ann	ual screening	Women of any age should not be screened annually by any screening method.	Individuals and clinicians can use the annual Pap test screening visit as an opportunity to discuss other health problems and preventive measures. Individuals, clinicians, and health systems should seek effective ways to facilitate the receipt of recommended preventive services at Intervals that are beneficial to the patient. Efforts also should be made to ensure that individuals are able to seek care for additional health concerns as they present.	in women aged 30-55 years, annual cervical cancer screening should not be performed. (Level A evidence) Patients should be counseled that annual well-woman visits are recommended even if cervical cancer screening is not performed at acach visit.	Not addressed.
Screening method ar	nd Intervals				
Cytology (conventional or	21–29 years of age	Every 3 years. <sup>d</sup>	Every 3 years (A recommendation).	Every 3 years (Level A evidence).	Not addressed.
liquid based) <sup>c</sup>	30–65 years of age	Every 3 years.d	Every 3 years (A recommendation).	Every 3 years (Level A evidence).	Not addressed.
HPV co-test (cytology + HPV	21–29 years of age	HPV co-testing should not be used for women aged <30 years.	Recommend against HPV co-testing in women aged <30 years (D recommendation).	HPV co-testing* should not be performed in women aged <30 years. (Level A evidence)	Not addressed.
test administered together)	30–65 years of age	Every 5 years; this is the preferred method.	For women who want to extend their screening interval, HPV co-testing every 5 years is an option (A recommendation).	Every 5 years; this is the preferred method (Level A evidence).	Not addressed.
Primary hrHPV testing <sup>f</sup> (as an alternative to cotesting or cytology alone) <sup>p</sup>		For women aged 30–65 years, screening by HPV testing alone is not recommended in most clinical settings. <sup>h</sup>	Recommend against screening for cervical cancer with HPV testing (alone or in combination with cytology) in women aged <30 years (D recommendation).	Not addressed.	Every 3 years. Recommend against primary hrHPV screening in women aged <25 years of age.!
When to stop screen	ing	Aged >55 years with adequate negative prior screening* and no history of CIN2 or higher within the last 20 years.   *Adequate negative prior screening results are defined as 3 consecutive negative cytology results or 2 consecutive negative co-lest results within the previous 10 years, with the most recent test performed within the past 5 years.	Aged >65 years with adequate screening history" and are not otherwise at high risk for cervical cancer (D recommendation).	Aged >65 years with adequate negative prior screening" results and no history of CIN 2 or higher (Level A evidence).	Not addressed.

## Cervical Cancer Screening Guidelines

TO THE CONTRACTOR OF T				
When to screen after age 65 years	Aged >65 years with a history of CIN2 CIN2, CIN3, or adenocarcinoma in situ, routine screening <sup>k</sup> should continue for at least 20 years.	Women aged >65 years who have never been screened, do not meet the criteria for adequate prior screening, or for whom the adequacy of prior screening cannot be accurately accessed or documented. Routine screening should continue for at least 20 years after spontaneous regression or appropriate management of a high-grade precancerous lesion, even if this extends screening past age 65 years.  Certain considerations may support screening in women aged > 65 years who are otherwise considered high risk (such as women with a high-grade precancerous lesion or cervical cancer, women with in utero exposure to diethylstitibestrol, or women who are immunocompromised).	Women aged >65 years with a history of CIN2, CIN3, or AIS should continue routine age- based screening <sup>8</sup> for at least 20 years (Level B evidence).	Not addressed.
Screening post-hysterectomy	Women who have had a total hysterectomy (removal of the uterus and cervix) should stop screening. <sup>11</sup> Women who have had a supra-cervical hysterectomy (cervix intact) should continue screening according to guidelines.	Recommend against screening in women who have had a hysterectomy (removal of the cervix) <sup>n</sup> (D recommendation).	Women who have had a hysterectomy (removal of the cervix) should stop screening and not restart for any reason <sup>no</sup> (Level A evidence).	Not addressed.
The need for a bimanual pelvic exam	Not addressed in 2012 guidelines but was addressed in 2002 ACS guidelines. <sup>9</sup>	Addressed in USPSTF ovarian cancer screening recommendations (draft). <sup>9</sup>	Addressed in 2012 well-woman visit recommendations. Aged <21 years, no evidence supports the routine internal examination of the healthy, asymptomatic patient. An "external-only" genital examination is acceptable. Aged ≥21 years, no evidence supports or refutes the annual pelvic examination or speculum and bimanual examination. The decision whether or not to perform a complete pelvic examination should be a shared decision after a discussion between the patient and her health care provider. Annual examination of the external genitalia should continue.*	Not addressed.
Screening among those immunized against HPV 16/18	Women at any age with a history of HPV vaccination should be screened according to the age specific recommendations for the general population.	The possibility that vaccination might reduce the need for screening with cytology alone or in combination with HPV testing is not established. Given these uncertainties, women who have been vaccinated should continue to be screened.	Women who have received the HPV vaccine should be screened according to the same guidelines as women who have not been vaccinated (Level C evidence).	Not addressed.

### **HPV Primary Screening**




#### Pap Smears/Rationale

- 2001 revised Bethesda system terminology for reporting cervical cytology results... standard approach for management. ASCCP developed management guidelines for unsatisfactory results
- 2006 2<sup>nd</sup> consensus conference aligned management of minor cytology abnormalities
- 2008 ASCCP guidelines were updated but not validated by national consensus conference
- 2012 National organizations published guidelines with longer screening intervals and later age to start screening. New evidence to guide decisions about abnormal findings
- 2012 ASCCP conducted a consensus process to update management of abnormal co-testing results and cytology with specimen adequacy limitations, initial management of abnormal screening results, options for postcolposcopy management, management of women aged 21-24 years, and other issues.
- 2014 FDA approved modified labeling of an hrHPV assay to include primary hrHPV screening for women 25 years and older

#### No Pap required!

- Do not screen in patients younger than 21 years of age
- Older than age 65:
  - IF adequate prior screening can be assessed accurately (3 consecutive negative cytology results or 2 consecutive negative HPV results within 10 years before screening cessation, with most recent test within the 5 years) and not otherwise at high risk for cervical cancer
- No cervix:
  - If the cervix was removed for benign reasons
- Recommendations DO NOT apply if:
  - Prior diagnosis of HSIL or cervical cancer
  - With in utero exposure to diethylstilbestrol (DES)
  - Immunocompromised women (HIV positive, organ transplant recipients, or chronic corticosteriod use)

# What happens if the Pap results say 'Unsatisfactory Cytology'?



#### Apps for Pap Smear Interpretation







#### Case Studies



#### Case Study #1


- 22-year-old, G2P1011; 2016 SVD male 8lbs 50z GHTN; EAB in 2011 at 8 weeks gestation; iron-deficiency anemia (daily iron supplementation); BMI 22; family hx of HTN (MGM); no other medical issues/history.
- States current monogamous relationship; positive chlamydia in 2015; states she is heterosexual
- No previous hx of Pap smear
- Desires contraception now but planning on trying to get pregnant in 1-2 years

#### Case Study #1

- Does this patient need a Pap smear?
  - Yes
- Would you screen for GC/CT?
  - Yes
- What contraceptives can she use? What would you recommend?
  - No restriction for Cu-IUD, LNG-IUD, Implant, DMPA, POP (1)
  - Advantage outweighs risk for CHC (2)
- What other counseling would you provide?
  - Preconception counseling; diet and exercise; adequate treatment of anemia; consider folic acid when actively trying to conceive.
- What is your next step if her Pap smear results ASCUS?

# Navigating the Pap App:






#### Case Study #2

- 33-year-old, G2P2002, SVDx2 (2007 & 2009) no complications; hypothyroidism (Synthroid 100mcg daily), CHTN (no meds), BMI 31; family hx of DM2 (mother, sister, maternal aunt, MGM).
- Recently divorced but has started dating again; states she is sexually active but not in a long-term relationship; states she is bisexual
- c/o vaginal discharge today with odor; has been present for "quite a while"; mild dysuria
- Last Pap 2016 (last year) resulted LSIL with negative HPV

Last Pap result recommendation:



#### Management of Women with Low-grade Squamous Intraepithelial Lesions (LSIL)\*†




© Copyright, 2013, American Society for Colposcopy and Cervical Pathology. All rights reserved. AS P




#### Case Study #2

- Does this patient need a Pap? Would you screen for HPV?
  - Yes and yes
- Would you screen for STDs? Which ones?
  - Yes; chlamydia, gonorrhea, trichomonas, could consider syphilis and HSV
  - Would also swab for candidiasis and bacterial vaginosis
- Would you counsel her about contraceptives? What options would you recommend for this patient?
  - Yes, if she does not desire children at this time; consider her medical hx of CHTN and obesity, do NOT recommend DMPA or CHC; If BPs are mild range, can consider IUDs, Implant or POP (1), if BPs are not well controlled, Cu-IUD
- What other counseling would you provide?
  - Safe sex practices, i.e. use of barrier devices to prevent STDs; not sharing sex toys and/or cleaning adequately after use; weight loss recommendation; diet and exercise recommendation; depression/mental health recommendation as indicated; diabetes screening; CHTN management; could consider thyroid screen if due

## Case #2: new Pap results – LSIL, HPV+



#### Management of Women with Low-grade Squamous Intraepithelial Lesions (LSIL)\*†



© Copyright, 2013, American Society for Colposcopy and Cervical Pathology. All rights reserved. AS P



#### Case Study #3

- 26 year-old, G1P0000; no significant medical history; BMI 23; occupation RN; family hx of DM2 (mother, MGF)
- Currently in a long-term, same-sex relationship; pregnancy via IVF;
   IVF transfer date 2 Aug 2017 giving EDC of 20 Apr 2018;
   approximately 10 weeks gestation
- Last pap June 2014, normal; no hx of STDs
- Today c/o mild nausea and breast tenderness; denies vaginal discharge or bleeding; denies abdominal cramping; denies dysuria


#### Case Study #3

- Does this patient need a Pap smear?
  - Yes
- Can you perform primary HPV screening on this patient?
  - Yes, she is a candidate
- Would you screen for STDs?
  - I screen all new OB patients for GC/CT, however, it's not required since she is 26 years old
- What other counseling would you provide?
  - Diet and exercise; universal precautions at work; lifting restrictions; recommend early diabetes screening due to family hx of first degree relative with DM2; refer for OB care if not provided in your clinic; include spouse in pregnancy appointments
- You choose to perform a Pap smear and the Pap results came back as ASCUS; what is your next step?

# Case Study #3: Pap results



#### Management of Women with Atypical Squamous Cells of Undetermined Significance (ASC-US) on Cytology\*



© Copyright, 2013, American Society for Colposcopy and Cervical Pathology. All rights reserved. AS P



#### Case Study #4

- 60 year-old, G6P6006; widowed x 8 years; s/p hysterectomy and bladder sling at age 48 for AUB and uterine prolapse, still has both ovaries; no significant medical hx; mild GERD symptoms, no medications; last mammogram normal; BMI 22
- Last Pap smear at age 50, normal, no HPV done; remote hx of abnormal Pap smear with normal colposcopy
- Recently (last 3 months) met a new guy at the bike shope when she had her mountain bike repaired; has started dating
- Today c/o vaginal dryness and itching with urge incontinence symptoms; would like to resume intercourse but experiences dyspareunia
- Physical exam: vaginal atrophy, pt unable to tolerate speculum or bimanual exam

#### Case Study #4

- Does this patient need a pap?
  - · No
- Would you screen for STDs?
  - Probably not unless directed by physical exam
- What would you recommend for this patient?
  - Trial of topical Premarin cream (1/2 g applied externally at bedtime x 2 weeks, then MWF thereafter); may consider topical lidocaine for severe symptoms if patient opposed to Premarin use; recommend external masturbation or use of vibrator to increase blood flow to the area (use it or lose it); follow up in 4-6 weeks for effectiveness.
- What additional counseling would you provide?
  - STD counseling; yearly mammograms; diet and exercise

#### Summary

- Well woman exams don't have to be intimidating
- Find a Pap app that you like and that is easy to use
- Keep up to date on new recommendations for Pap smear schedules and STD treatment
- Be aware of what STDs are hot in your area
- Educate, educate, educate!

#### References:

- Carcio, H. N., & Secor, M. C. (2015). Advanced health assessment of women: Clinical skills and procedures (3rd ed.). New York: Springer Publishing Company, LLC.
- Center. (2015). Sexually transmitted diseases: Summary of the 2015 CDC treatment guidelines [Pamphlet]. Department of Health and Human Services.
- Centers for Disease Control and Prevention. (2014, June 30). Screening recommendations and considerations referenced in the 2015 STD treatment guidelines and original sources. Retrieved September 2, 2017, from https://www.cdc.gov/std/prevention/screeningreccs.htm
- Centers for Disease Control and Prevention. (2016). Alaska State Health Profile (United States, Centers for Disease Control and Prevention, Department of Health and Human Services). Retrieved September 1, 2017, from https://www.cdc.gov/nchhstp/stateprofiles/pdf/Alaska\_profile.pdf

#### References

- Centers for Disease Control and Prevention. (2016). Reported STDs in the United States: 2015 national data for chlamydia, gonorrhea, and syphilis [Pamphlet]. Department of Health and Human Services.
- Centers for Disease Control and Prevention. (2017, July 03). Sexually Transmitted Diseases (STDs). Retrieved September 1, 2017, from https://www.cdc.gov/std/ept/default.htm
- Huh, W. K., Ault, K. A., Chelmow, D., Davey, D. D., Goulart, R. A., Garcia, F. A., . . . Einstein, M. H. (2015). Use of primary high-risk human papillomavirus testing for cervical cancer screening: Interim clinical guidance. *Journal of Lower Genital Tract Disease*, 19(2), 91-96. doi:10.1097/LGT00000000000000
- Massad, L. S., Einstein, M. H., Huh, W. K., Katki, H. A., Kinney, W. K., Schiffman, M., . . . Lawson, H. W. (2013). 2012 Updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Journal of Lower Genital Tract Disease, 17(5), S1-S27.
- Secor, M. C., & Fantasia, H. C. (2012). Fast facts about the gynecologic exam for nurse practitioners: Conducting the GYN exam in a nutshell. New York: Springer.

#### Thanks!!

